Thermo Fisher Scientific and Groupe Novasep have announced Thermo Fisher has completed its acquisition of Henogen, Novasep’s viral vector manufacturing business in Belgium, for approximately $875.7 million in cash.
The business provides contract manufacturing services for vaccines and therapies to biotechnology companies and biopharma customers. With two locations in Seneffe and Gosselies, Belgium, Henogen offers more than 7000 sqm of clinical and commercial manufacturing capacity. The business has approximately 400 employees with operational and technical expertise in range of viral vector classes.
“Novasep’s viral vector business is an excellent strategic fit as Thermo Fisher continues to expand its capabilities for cell and gene vaccines and therapies globally,” said Michel Lagarde, Executive VP of Thermo Fisher. “The addition of its manufacturing capabilities in Europe complements our four development and manufacturing sites in North America. In addition, it brings an incredibly talented team with more than two decades of experience across a broad range of viral vectors. The combination will benefit our global customers seeking support and capacity in the region as well as European customers bringing new medicines to patients inside and outside of Europe.”
Michel Spagnol, President and CEO of Novasep said, “Thermo Fisher is an outstanding partner for our viral vector business and its future development. Our diverse customer base will benefit from the combination of our viral vector services capabilities with the scale and capabilities of Thermo Fisher. Our talented employees will bring deep expertise to an organisation that shares our commitment to providing ground-breaking new medicines to patients.”
